Ocrelizumab: A Review in Multiple Sclerosis.

CNS Drugs
Yahiya Y Syed

Abstract

Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). In the two identically designed, 96-week OPERA I and II trials in patients with RMS, ocrelizumab significantly reduced annualized relapse rates versus interferon β-1a. In the ≥ 120-week ORATORIO trial in patients with PPMS, ocrelizumab significantly reduced the risk of ≥ 12-week confirmed disability progression relative to placebo. These primary endpoint results were supported by a number of secondary outcomes, including disease activity in the brain assessed by magnetic resonance imaging. Ocrelizumab was generally well tolerated in these studies, with infusion-related reactions and infections being the most common adverse events, which were mostly mild to moderate in severity. In summary, ocrelizumab is a novel high-efficacy disease-modifying therapy for RMS that is more effective than interferon β-1a and also a valuable new treatment option for delaying progression in early PPMS. It offers a convenient once every 6 months treatment regimen, with no need for routine monitoring.

References

Jan 21, 2016·Therapeutic Advances in Neurological Disorders·Per Soelberg Sorensen, Morten Blinkenberg
Nov 5, 2016·Expert Review of Neurotherapeutics·Alberto GajofattoMaria Donata Benedetti
Dec 22, 2016·The New England Journal of Medicine·Stephen L HauserUNKNOWN OPERA I and OPERA II Clinical Investigators
Dec 22, 2016·The New England Journal of Medicine·Xavier MontalbanUNKNOWN ORATORIO Clinical Investigators
Jul 8, 2017·Brain Sciences·Narges DargahiVasso Apostolopoulos
Jul 12, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jeffrey M GelfandStephen L Hauser
Sep 28, 2017·International Journal of Molecular Sciences·Klaus Lehmann-HornMartin S Weber
Jan 21, 2018·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·X MontalbanF Zipp
Mar 24, 2018·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Eva HavrdováGavin Giovannoni

❮ Previous
Next ❯

Citations

Apr 28, 2019·Expert Opinion on Biological Therapy·Mihai AncauBernhard Hemmer
Feb 26, 2019·Frontiers in Immunology·Smita Y PatelStephen Jolles
Dec 9, 2020·Biologicals : Journal of the International Association of Biological Standardization·Kavina ShahVenkat Reddy
Dec 29, 2020·Annals of Clinical and Translational Neurology·Eva Fernandez-DiazAngel P Sempere
Feb 2, 2021·Frontiers in Neurology·Angel P SempereAntonio Palazón-Bru
Apr 23, 2021·Clinical Drug Investigation·Domenico PlantoneGiuseppe Rinaldi
Jul 4, 2021·Multiple Sclerosis and Related Disorders·Dominika StastnaDana Horakova
Jul 11, 2021·Multiple Sclerosis and Related Disorders·Maria José SáAna Macedo
Nov 24, 2021·The Journal of Immunology : Official Journal of the American Association of Immunologists·Patrick O'ConnellAndrea Amalfitano

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Therapeutic Advances in Neurological Disorders
Patricia MuleroXavier Montalban
Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics
Jeffrey M GelfandStephen L Hauser
© 2022 Meta ULC. All rights reserved